کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3210127 | 1587608 | 2009 | 5 صفحه PDF | دانلود رایگان |

BackgroundThrombocytopenia has been reported to be associated with efalizumab therapy, but has only sporadically been reported with other anti–tumor necrosis factor alfa (TNF-α) agents.ObjectiveTo describe the frequency of thrombocytopenia in a cohort of patients who underwent biological therapies for psoriasis.MethodsThis was a retrospective observational study of 93 patients.ResultsOne hundred eighteen courses of biological therapies were administered to 93 patients. Four of 67 patients who received anti-TNF-α agents developed drug-induced thrombocytopenia during treatment, compared with none of the 51 patients receiving efalizumab therapy. The platelet count recovered after suspension of anti-TNF-α agents in 3 patients and relapsed after re-exposure in two patients. The overall estimated frequency of thrombocytopenia in our cohort was 4.30% (95% confidence interval [CI], 0% to 6.2%).LimitationsThese findings should be validated in larger studies.ConclusionsDrug-induced thrombocytopenia is a potential side effect of anti-TNF-α agents. Immediate monitoring of platelet counts is recommended if autoimmunity is suspected.
Journal: Journal of the American Academy of Dermatology - Volume 60, Issue 5, May 2009, Pages 781–785